Notice regarding agreement to terminate joint research contract with Japanese Foundation for Cancer Research

2018.02.14 Information

--To the press -

Notice regarding agreement to terminate joint research contract with Japanese Foundation for Cancer Research

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Mothers)
(NASDAQ ticker symbol: FRONTEO)

Our subsidiary FRONTEO Healthcare Co., Ltd. (hereinafter, "FRONTEO Healthcare") and the Japanese Foundation for Cancer Research jointly aimed at the development of "Cancer Personalized Medical AI System" on January 2017, 31. We have signed a research contract and have continued our research, and although we have achieved some results, we have agreed that we will not enter the next step toward development.
 
FRONTEO Healthcare will continue to work on research and development of "personalized medicine" that selects treatment methods and drugs suitable for individual patients.With our artificial intelligence technology that realizes more effective utilization of various medical information such as a huge amount of literature information updated daily, medical / nursing records, genetic information, etc., medical professionals including doctors and comedy, and health We will support all professionals involved in care.
 
The impact of this matter on the business results for the fiscal year ending March 2018 will be minor.

For further information, please contact

FRONTEO Inc. Public Relations
pr_contact@fronteo.com
ja 日本語
Machine Translation by Google. : close x